Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma

Tang, Qing-Nan; Liu, Liting; Qi, Bin; Guo, Shan-Shan; Luo, Dong-Hua; Sun, Rui; Sun, Xia; Chen, Dongping; Guo, Ling; Mo, Hao‐Yuan; Wang, Pan; Liu, Sai-Lan; Liang, Yu-Jing; Li, Xiaoyun; Yang, Zhen-Chong; Chen, Qiuyan; Mai, Hai‐Qiang

doi:10.1001/jamanetworkopen.2021.38470

Cited by 14 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent comments [ 30 ] indicate that it is too early to conclude that nedaplatin will replace cisplatin. However, the newly published results of the 5-year follow-up still support the results of the initial report [ 17 ].…”

Section: Discussionsupporting

confidence: 58%

“…Long-term side effects such as nausea, vomiting, auditory function, renal function, or effects on peripheral nerves caused by cisplatin may affect the quality of life of survivors. Moreover, cisplatin-based CCRT requires pretreatment and post-treatment hydration during cisplatin administration to protect the kidneys, which can prolong the hospital stay [ 14 , 16 , 17 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis

Li²,

Yang

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background Cisplatin-based concurrent chemoradiotherapy has been identified as the primary and standard treatment for locally advanced nasopharyngeal carcinoma (NPC). However, the side effects of cisplatin affect the compliance to therapy. Thus, the search for a platinum-based substitute for NPC has always been a research focus. However, there is a variability in the efficacy of different platinum-based chemotherapies in the treatment of NPC. We performed a meta-analysis to compare the efficacy and safety of cisplatin-based regimens and other platinum-based derivatives (carboplatin, nedaplatin, and lobaplatin) for locally advanced NPC. Methods PubMed, EMBASE, Cochrane Library, Web of Science, and ClinicalTrials.gov were systematically searched for all potentially eligible clinical trials as of February 15, 2022. The pooled hazard ratios, risk ratio, and 95% confidence interval were calculated using Review Manager Software version 5.4. Results A total of 1,907 patients with locally advanced NPC were eligible from the 1,265 retrieved records. This systematic review included eight articles, six of which were randomized controlled clinical trials. There was no significant difference in the 3- and 5-year overall survival, progression-free survival, distant metastasis-free survival, and locoregional relapse-free survival between cisplatin-based chemotherapy and other platinum-based chemotherapy. Severe acute hematological side effects (≥ grade 3) during treatment, such as neutropenia, leukopenia, and thrombocytopenia, were equivalent in both groups. However, the incidence of anemia was higher in patients receiving other platinum-based chemotherapies. The risk of nausea, vomiting and weight loss was higher in the cisplatin group; however, there was no significant difference in the other non-hematological and late side effects between the two groups. Conclusions Other types of platinum-based chemotherapies are as effective as cisplatin-based chemotherapy in the treatment of locally advanced NPC, thus acting as potential alternatives to cisplatin. Further studies providing high-level evidence are needed.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis

Li²,

Yang

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Subsequent comments [32] indicate that it is too early to conclude that nedaplatin will replace cisplatin. However, the newly published results of the 5-year follow-up still support the results of the initial report [17].…”

Section: Discussionsupporting

confidence: 65%

“…Long-term side effects such as nausea, vomiting, auditory function, renal function or effects on peripheral nerves caused by cisplatin may affect the quality of life of survivors. Moreover, cisplatin-based CCRT requires pretreatment and post-treatment hydration during cisplatin administration to protect the kidneys, which can prolong the hospital stay [14,16,17].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparing the Efficacy and Safety of Cisplatin and other Platinum-based Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

Kang

et al. 2022

Preprint

View full text Add to dashboard Cite

Objectives: Cisplatin-based concurrent chemoradiotherapy has been identified as the primary and standard treatment for locally advanced nasopharyngeal carcinoma (NPC). The side effects of cisplatin affect the compliance to therapy. Thus, the search for a platinum-based substitute for NPC has always been a research focus. However, there is a variability in the efficacy of different platinum-based chemotherapy in the treatment of NPC. We performed a meta-analysis to compare between the efficacy and safety of the cisplatin-based regimens and the other platinum-based derivatives (carboplatin, nedaplatin, and lobaplatin) for locally advanced NPC. Methods: PubMed, EMBASE, Cochrane Library, Web of Science, and ClinicalTrials.gov were systematically searched for all potentially eligible clinical trials as of February 15, 2022. The pooled hazard ratios, risk ratio, and 95% confidence interval were calculated using the Review Manager Software version 5.4. Results: A total of 1,907 patients with locally advanced NPC were eligible from the 1,265 retrieved records. This systematic review included eight articles, six of which were randomized controlled clinical trials. There was no significant difference in the 3- and 5-years overall survival, progression-free survival, distant metastasis-free survival, and locoregional relapse-free survival between cisplatin-based chemotherapy and other platinum-based chemotherapy. Severe acute hematological side effects (≥ grade 3) during treatment, such as neutropenia, leukopenia, and thrombocytopenia, are equivalent in both groups. However, the incidence of anemia is higher in patients receiving other platinum-based chemotherapy. Moreover, the risks of nausea, vomiting and weight loss were higher in the cisplatin group but there was no significant difference in the other non-hematological and late side effects between the two groups. Conclusion: Other types of platinum-based chemotherapy are as effective as cisplatin-based chemotherapy in the treatment of locally advanced NPC, thus acting as potential alternatives to cisplatin. Further studies providing high-level evidence are needed.

show abstract

Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease

et al. 2023

View full text Add to dashboard Cite

Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma

Cited by 14 publications

References 30 publications

Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis

Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis

Comparing the Efficacy and Safety of Cisplatin and other Platinum-based Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease

Contact Info

Product

Resources

About